Oxaliplatin plus gemcitabine as a salvage schedule for hormone-refractory prostate adenocarcinoma.
We report a case of hormone-refractory prostate cancer (HRPC) treated with oxaliplatin plus gemcitabine in a third-line schedule after liver progression, with an excellent clinical, biochemical and radiological response and with an acceptable tolerance. Prior chemotherapy regimens included docetaxel plus estramustine and oral etoposide. To our knowledge, this is the first report that shows this approach in an HRPC patient.
Santisteban
M
M
Medical Oncology Department, Clínica Universitaria de Navarra, Pamplona, Spain. santisteban.marta@mayo.edu
Pérez-Gracia
J L
JL
Ceballos
J
J
Vivas
I
I
García-Foncillas
J
J
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D016879:Salvage Therapy / Q000379:methods*; D014057:Tomography, X-Ray Computed; D000093542:Gemcitabine
D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D003841:Deoxycytidine; D017430:Prostate-Specific Antigen; D000093542:Gemcitabine